TAP Pharmaceutical Products Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Prevacid® (lansoprazole) for the short-term treatment of symptomatic gastroesophageal reflux disease (GERD) and erosive esophagitis in children from the ages of 1 to 11 years old.
Currently, Prevacid is the most prescribed* proton pump inhibitor (PPI) in the United States. “Although people often think of GERD as an adult condition, many children are affected by it,” said Benjamin Gold, M.D., director of pediatric gastroenterology and nutrition at Emory University School of Medicine.
“It is important that there are FDA-approved treatment options for children who experience the often painful effects of GERD.” GERD is one of the most common esophageal disorders in children. When stomach contents, such as food and gastric acid, frequently reflux out of the stomach and into the esophagus, esophageal tissue damage may occur.
Common symptoms in children include regurgitation (spitting up), chest pain (heartburn), abdominal pain, feeding resistance and difficulty swallowing.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!